Cardiac 123I-MIBG scintigraphy in heart failure

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 52, Issue 4, 2008, Pages 369-377

  Agostini, D ^a   Verberne, H J ^b   Hamon, M ^a   Jacobson, A F ^c   Manrique, A ^a  

^a CHU CÔTE DE NACRE   (France)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c GE HEALTHCARE   (United States)

Author keywords

3 Iodobenzylguanidine; Arrhythmias, cardiac; Heart failure; Prognosis; Radionuclide imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE; TETROFOSMIN TC 99M; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT;

CARDIOMYOPATHY; CLINICAL TRIAL; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART DEATH; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SCINTISCANNING; HUMAN; INTERMETHOD COMPARISON; PREDICTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC INNERVATION; HEART; HEART MUSCLE; PATHOLOGY; PROSPECTIVE STUDY; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; HEART; HEART FAILURE; HUMANS; MYOCARDIUM; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 60549101710     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC et al. The epidemiology of heart failure. Eur Heart J 1997; 18:208-25.
2. Ahmed A. A propensity matched study of New York Heart Association class and natural history end points in heart failure. Am J Cardiol 2007;99:549-53.
3. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005;26:1115-40.
4. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-e235.
5. Turakhia M, Tseng ZH. Sudden cardiac death: epidemiology, mechanisms, and therapy. Curr Probl Cardiol 2007;32:501-46.
6. Wafelman AR. Metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 1994;21:545-59.
7. Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981;22:129-32.
8. Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987;28:1625-36.
9. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.
10. Agostini D, Lecluse E, Belin A, Darlas Y, Dronne E Grollier G et al. Impact of exercise rehabilitation on cardiac neuronal function in heart failure: an iodine-123 metaiodobenzylguanidine scintigraphy study. Eur J Nucl Med 1998;25:235-41.
11. 123I-mIBG in the fading human heart. J Nucl Med 1999; 40:224-31.
12. Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Rande JL, Duval AM et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917-23.
13. Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Hashimoto A, Ogata H et al. Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. J Card Fail 2003;9:113-21.
14. Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999;33:759-66.
15. 123I-mIBG scintigraphic study. J Nucl Med 2000;41:845-51.
16. Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001;42:1757-67.
17. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002;43:1279-85.
18. Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure. A prospective study. J Am Coll Cardiol 2003;41:231-8.
19. Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med 2004;45:155-63.
20. Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging 2005;32:186-94.
21. Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F et al. I-123 mIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121-31.
22. Paul M, Schafers M, Kies P, Acil T, Schafers K, Breithardt G et al. Impact of sympathetic innervation on recurrent life-threatening arrhythmias in the follow-up of patients with idiopathic ventricular fibrillation. Eur J Nucl Med Mol Imaging 2006;33:866-70.
23. Nagahara D, Nakata T, Hashimoto A, Wakabayashi T, Kyuma M, Noda R et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med 2008;49:225-33.
24. Bonow RO, Bennett S, Casey DE Jr., Ganiats TG, Hlatky MA, Konstam MA et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J Am Coll Cardiol 2005; 46:1144-78.
25. Radford MJ, Arnold JM, Bennett SJ, Cinquegrani MP, Cleland JG, Havranek EP et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Failure Society of America. Circulation 2005;112:1888-916.
26. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
27. 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147-59.
28. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008;35:535-46.
29. Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies. J Nucl Cardiol 2004;11:126-33.
30. 123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. Heart 1996;76:218-22.
31. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997;38:1085-9.
32. de Milliano PA, cle Groot AC, Tijssen JG, van Eck Smit BL, van Zwieten PA, Lie KI. Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure. Am Heart J 2002;144:E3.
33. Eichhorn EJ, McGhie AL, Bedotto JB, Corbett JR, Malloy CR, Hatfield BA et al. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol 1991;67:67-73.
34. Gerson MC, Craft LL, McGuire N, Suresh DP, Abraham WT, Wagoner LE. Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol 2002;9:608-15.
35. Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy - Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single hoton emission computed tomography. Am Heart J 2001;141:45-52.
36. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:574-81.
37. Ehlert FA, Carmom DS, Renfroe EG, Greene HL, Ledingham R, Mitchell LB et al. Comparison of dilated cardiomyopathy and coronary artery disease in patients with life-threatening ventricular arrhythmias: differences in presentation and outcome in the AVID registry. Am Heart J 2001;142:816-22.
38. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannon DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
39. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
40. Skrabal MZ, Stading JA, Behmer-Miller KA, Hilleman DE. Advances in the treatment of congestive heart failure: new approaches for an old disease. Pharmacotherapy 2000;20:787-804.
41. Al-Khatib SM, Sanders GD, Mark DB, Lee KL, Bardy GH, Bigger JT et al. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J 2005; 149:1020-34.
42. Bukharovich IF, Kukin M. Optimal medical therapy for heart failure. Prog Cardiovasc Dis 2006;48:372-85.
43. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353:1471-80.
44. Gehi AK, Stein RH, Metz LD, Gomes JA. Microvolt T-wave alternans for the risk stratification of ventricular tachyarrhythmic events: a meta-analysis. J Am Coll Cardiol 2005;46:75-82.
45. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R et al.; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-8.
46. Kioka H, Yamada T, Mine T, Morita T, Tsukamoto Y, Tarnaki S et al. Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart 2007;93:1213-8.
47. Higuchi T, Schwaiger M. Imaging cardiac neuronal function and dysfunction. Curr Cardiol Rep 2006;8:131-8.
48. 123I-metaiodobenzylguanidine scintigraphy in the detection of irregular regional sympathetic innervation in long QT syndrome. Eur Heart J 1993;14:316-25.
49. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-11): a randomised trial. Lancet 1999;353:9-13.
50. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
51. Kammerling JJ, Green FJ, Watanabe AM, Inoue H, Barber MJ, Henry DP et al. Denervation supersensitivity of refractoriness in noninfarcted areas apical to transmural myocardial infarction. Circulation 1987;76:383-93.
52. 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation. Eur J Nucl Med Mol Imaging 2008;35:547-53.
53. Port SC, editor. Imaging guidelines for nuclear cardiology procedures, Part 2. J Nucl Cardiol 1999;6:G49-G84.
54. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-42.
55. 123I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multicenter pilot study. Circ Cardiovasc Imaging 2008; 1:131-40.
56. Bax JJ, Boogers M, Henneman M. Can cardiac iodine-123 metaiodobenzylguanidine imaging contribute to risk stratification in heart failure patients? Eur J Nucl Med Mol Imaging 2008;35: 532-4.